$CGON — The Bladder Cancer Short Squeeze Setup Nobody Is Talking About
Alright regards, gather around.
This is not another “company added AI to the homepage so number go up” garbage post. This is a biotech binary catalyst setup with actual squeeze mechanics, a real Phase 3 readout window, serious institutional attention, and shorts sitting on a barrel of gasoline while management is walking around with a lighter.
Ticker: CGON
Company: CG Oncology
Market cap: roughly $5B
Sector: late-stage biotech / bladder cancer
Main drug: cretostimogene grenadenorepvec
Main catalyst: PIVOT-006 Phase 3 topline data expected in 1H 2026
Sources for the lazy:
CGON official PIVOT-006 timeline update
CGON Q1 2026 business update
CGON clinical pipeline
PIVOT-006 on ClinicalTrials.gov
CGON short interest via MarketBeat
CGON short interest via Nasdaq
CGON SEC filings
Translation for the smooth-brained:
Data is expected before the end of June 2026 unless the company delays. Shorts are crowded. If data is clean, this thing can violently re-rate. If data sucks, yes, you can get your face ripped off. Welcome to biotech.
The setup
CGON is developing an intravesical oncolytic immunotherapy for non-muscle invasive bladder cancer, which means the drug is delivered directly into the bladder instead of nuking the whole body like traditional systemic therapy.
The company already has a high-risk bladder cancer program, but the real “oh shit” catalyst is PIVOT-006, a Phase 3 randomized trial in intermediate-risk NMIBC.
Official trial page: PIVOT-006 / NCT06111235
Why does that matter?
Because intermediate-risk NMIBC is a larger, earlier-treatment population. This is not just “last resort drug for desperate patients.” This is potentially a much broader bladder cancer commercial opportunity.
If PIVOT-006 hits cleanly, the story changes from:
“Interesting biotech with bladder cancer data”
to:
“Potential backbone therapy across a much larger NMIBC market.”
That is the kind of narrative shift that can make shorts start sweating through their Patagonia vests.
The catalyst window
Management has guided for PIVOT-006 topline data in 1H 2026.
That means the market is now in the danger zone.
CGON announced that it moved the topline timeline forward to the first half of 2026, nearly one year ahead of schedule, because of rapid enrollment across 90+ sites and 360+ patients.
Official source: CGON PIVOT-006 timeline update
That matters because fast enrollment can signal actual physician/site interest, not just biotech PowerPoint hopium.
Again, not proof the trial works. But it means this is not some dead microcap running a fake “promising data soon bro” story from a rented WeWork.
The short squeeze mechanics
This is where it gets spicy.
Latest short-interest sources show CGON with meaningful short interest and high days-to-cover.
MarketBeat shows:
11.68% of float short
10.15 days to cover
Short interest recently increased
Source: MarketBeat CGON stock and short-interest data
Nasdaq also has a dedicated short-interest page here:
[Nasdaq CGON short interest](https://www.nasdaq.com/market-ac